Research Article

Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to Radiotherapy Led to an Observed Improvement in Survival—A Single Centre Experience and Review of the Literature

Natalie M. Lowe,1 Sean Loughran,2 Nicholas J. Slevin,3 and Beng K. Yap3

1 Head and Neck Surgery, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
2 Head and Neck Surgery, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
3 Head and Neck Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK

Correspondence should be addressed to Beng K. Yap; beng.yap@christie.nhs.uk

Received 23 August 2013; Accepted 11 September 2013; Published 17 February 2014

Academic Editors: H.-J. Biersack, H. J. Gallowitsch, and H. Zitzelsberger

Copyright © 2014 Natalie M. Lowe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Anaplastic thyroid carcinoma (ATC) is rare, representing only 1–2% of all thyroid cancers, but nevertheless accounts for up to 50% of all thyroid cancer deaths [1–6]. Survival time is generally short with one-year survival rates being reported at 10–20% [6–10]. Long-term survival is rare and can lead to doubts about diagnosis [3, 6–8]. With the small number of patients diagnosed with ATC and the rapid progression of the disease, there is little consensus about the best treatment approach for newly diagnosed patients or in which order the treatment modalities should be offered [6, 11, 12]. The American Thyroid Association has recently published guidelines for the management of patients with ATC, [13], though despite an extensive review of the literature to produce these guidelines, the quality of evidence available to produce the 65 recommendations is reported by the authors as being either low or moderate only. This paper aims to discuss our experience and outcomes of a series of 20 consecutive patients referred to a tertiary oncology unit with a diagnosis of ATC. Patterns noticed within the outcomes will be compared to the current literature and recommendations. How dismal outcomes may be improved will also be considered.

2. Findings at Our Institution

2.1. Materials and Methods.

We searched for all cases of ATC in our institutional prospective thyroid cancer database from 2004 to 2011. Patients were only included into the study when they had histologically confirmed ATC via core biopsy or surgical specimen based on WHO classification. All patients
had already been deemed not suitable for surgery or further surgery by their referring thyroid surgeons. Our institutional practice was to offer radiotherapy only in 2004–2007. Due to the disappointing outcome, we introduced chemotherapy in our institutional protocol since 2008 to be followed by surgery by their referring thyroid surgeons. Our institutional protocol was to offer radiotherapy only in 2004–2007. Due to the disappointing outcome, we introduced chemotherapy to the patients. Two patients had tracheostomies, one of whom died from asphyxiation. The mode of death was not known in one of the patients. Two patients had tracheostomies, one of whom died from asphyxiation.

2.2. Results. 20 out of 1030 patients in the thyroid cancer database met ATC criteria and hence were included in the final review. The ratio of female to male subjects was 9 female to 11 male (ratio 1:1.2) with the median age at diagnosis being 69.5 years (range 56.3–80.56 years).

2.3. Pattern of Spread at Presentation. 12 patients (60%) were found to have metastatic disease at presentation. All of these were found to have lung metastases; of these, 12, two also had bone metastases, one had adrenal metastases, one had brain metastases, and one had hepatic metastases.

2.4. Mode of Death. 19 patients (95%) died due to the anaplastic thyroid carcinoma or as a consequence of its complications, eight (40%) of whom died specifically from asphyxiation. The mode of death was not known in one of the patients. Two patients had tracheostomies, one of whom died from asphyxiation.

2.5. Survival. Median survival for all cases was 59 days (ranging from 32 to 350 days plus one long-term survival (eight years plus)) (calculated from date first seen at our centre rather than the referring institution). One patient is still alive, with no signs of recurrence greater than eight years since diagnosis. This is the only person to have survived a year or more (1 year survival rate = 5%). Table 1 shows the number of patients having each treatment regimen and their median survival plus the percentage of each treatment group that died from asphyxiation.

The median survival of all treatment groups of patients who had surgery prior to referral was found to be 142 days (range 32 days–eight years+) compared to a median survival of 59 days (range 32–350 days) for those who had not had surgery. Chemotherapy followed by radiotherapy however produced the longest median survival out of all treatment modalities at 220 days (range 52–350 days).

2.6. Performance Status. On analysis of the World Health Organisation (WHO) performance scores for patients receiving different treatment modalities, our series showed a good spread of WHO scores. Hence, outcomes to different treatment modalities could not be specifically attributed to this.

3. Comparison with the Current Literature

3.1. Survival. In line with current consensus, we found ATC to usually be a disease of the elderly (median age at diagnosis: 69.5 years (range 56.3–80.56 years)). Our series showed a slight male preponderance (1:1.2) which is reflected by some studies [6], but many suggest a greater female preponderance [7, 8, 12, 14, 15]. As reflected in previous studies, the prognosis and one-year survival rates for these patients with ATC were poor [6, 7, 9, 10]. Our series demonstrated the median survival to be 59 days and a one-year survival rate of 5% from time of first consultation at our institution. The one-year survival is lower than other previously reported studies (10–20%) [6, 7, 9, 10]. However, comparison with older studies is complicated by uncertainty of histological diagnosis in some studies. Some histopathology specimens that might have historically been labelled as anaplastic would actually now be labelled as other types of carcinoma using today’s criteria, which may be either less aggressive or have a better response to the nonsurgical treatment modalities such as non-Hodgkin’s lymphoma [3, 6–8]. Indeed, the US national database from 1985 to 1995 reports a 5-year survival as high as 55% in certain groups of patients (aged <46 years old); however, this also reports that there had been no independent pathology review [14]. The current definition and histological findings of ATC as stated by the WHO are shown as follows [16].
WHO Classification of Tumours: Undifferentiated/Anaplastic Thyroid Carcinoma [16]:

Undifferentiated Thyroid Carcinomas (UTC) are highly malignant tumours that histologically appear wholly or partially composed of undifferentiated cells that exhibit immunohistochemical or ultra-structural features indicative of epithelial differentiation. Histologically they are composed of a mixture of spindle cells, pleomorphic giant cells and epithelial cells. There is considerable variation in both the percentage and distribution of these cellular elements from case to case.

3.2. Surgery. Our study showed that the seven patients who had previous surgery had a longer median survival (142 days; range 38 days–8 years) as compared to the 13 patients who had not had previous surgery (59 days; range 32–350 days). The only long-term survivor in our series also had surgery prior to radiotherapy, a treatment strategy that was also shown to significantly increase survival by Kobayashi et al. [17]. Haigh et al. [12] performed an analysis of 33 patients reporting that multivariate analysis of the factors associated with significant survival differences revealed that potentially curative surgery was the only discriminating variable that retained a significant association with prolonged survival. Our data would support this view that surgery is an important modality of treatment in the management of ATC, and when feasible, we would recommend it as part of multimodality treatment. Obviously, there is a potential bias towards surgery being done in fitter patients with less advanced local disease; however, in our series there was a good spread of performance statuses across both groups. Contrary to expectations, the median performance status was lower in the nonsurgical group (WHO PS = 0) compared to the surgical group (WHO PS = 1), which also included the patient with the poorest performance status in the whole series (WHO PS = 3).

Further surgery was not offered following referral to our institution as it was deemed not beneficial by the referring thyroid surgeons; therefore, only 35% of the series had any form of surgery as part of their treatment. This may have contributed to the poor survival in our series as compared to other series [6, 7, 9, 10] which may have been more aggressive in offering surgical treatment.

3.3. Radiotherapy. Our institutional protocol from 2004 to 2007 was to offer radiotherapy in the postoperative setting and for inoperable cases. The median dose given was 30 Gy (range 24–65 Gy). The median survival in the radiotherapy only group was 59 days (range 42–206 days) from first consultation at our institution. This is similar to the overall median survival for the entire cohort (59 days) and only 27 days greater than no treatment at all. These dismal outcomes lead to the change of our institutional protocol by the addition of chemotherapy since 2008. However, studies often suggest that radiotherapy is worthwhile as it does improve outcome, especially when performed after surgery [6, 8, 9]. This result was reflected in our series in which patients who had received radiotherapy after surgery had a median survival of 176 days (range 4 days–8 years+) and improved from 38 days from surgery alone.

3.4. Chemotherapy. Six patients in our series had chemotherapy, 3 of these were in combination with radiotherapy. The median survival of patients treated with chemotherapy as a single therapy agent was 137 days (range 41–175 days) which was improved from other single agent treatment modalities (surgery 38 days (range 32–238 days) and radiotherapy 58.5 days (range 42–206 days)). Combining chemotherapy with radiotherapy (median dose 45 Gy; range 30 Gy–55 Gy) produced the longest median survival in our series at 220 days (range 52–350 days) even when compared to surgically treated patients, although chemotherapy was not given in combination with surgery in this series. Contrary to expectations, the chemotherapy plus radiotherapy treatment group had the highest median WHO PS in our series (median PS = 1 compared to 0 in radiotherapy and chemotherapy groups), and hence good results could not be solely attributed to this. Although these results are too small to draw definite conclusions from, they do correspond with several other studies that suggest that chemotherapy is of benefit in the management of ATC [10, 12, 18] rather than with some studies which did not find any proven benefit [9, 11, 19]. Our series highlighted the important question of balancing possible modest improvement in survival versus quality of life. We defined 6 cycles of chemotherapy to be the intended course length of chemotherapy. However, 5 out of 6 (83%) patients did not finish their intended course due to poor tolerance and side effects. The median number of cycles of chemotherapy actually received was 3 (range 2–6). In retrospect, the 6 intended courses of chemotherapy may have been overly ambitious.

3.5. Asphyxiation. ATC often presents with locally advanced large tumours as shown in the CT scan in Figure 1. Death in ATC patients is often therefore caused by tracheal and...
oesophageal invasion and obstruction, as well as by consequences of metastatic disease. We found that 8 out of 20 patients (40%) died from asphyxiation. All the 3 patients who received chemotherapy followed by radiotherapy died of asphyxiation in our series. This group had the longest median survival time and hence perhaps allowed time for local tumour growth. As with our practice, several centres offer radiotherapy as palliation to prevent local and compression symptoms. However, our series showed that the number of deaths from asphyxiation was the same for all patients receiving single modality treatments such as radiotherapy (33%), chemotherapy (33%), and surgery (33%) (see Table 1). These results may be borne in mind when only offering palliative dose radiotherapy to prevent local and compression symptoms as is often done [3, 7, 11, 18].

4. Discussion: How Can Outcomes Be Improved?

4.1. Correct and Swift Diagnosis. In order to improve outcomes for patients with ATC, it is first vital to get a correct and swift diagnosis so that treatment choice can be tailored to their needs. Correct histopathological diagnosis is essential in order to differentiate ATC from other less aggressive and more treatable tumours that can mimic ATC closely. Samples can be obtained from either fine needle aspiration techniques, core biopsy, or open biopsy [13]. ATC is a rapidly progressing disease and hence once formally diagnosed, although clinical assessment of the extent of the local, regional, and distant disease should ideally be obtained, as per the ATA guidelines for the treatment of ATC, these investigations (such as the biopsy of suspected metastatic disease) should not delay the definitive treatment [13]:

It is vital to get a correct and swift diagnosis of ATC; differentiating it from other less aggressive diagnoses that can mimic closely. Further investigations such as the biopsying of suspected metastatic disease should not delay the prompt initiation of definitive treatment.

4.2. Surgery. A decision should be made initially whether the tumour is resectable or unresectable. Most studies suggest that treatment regimens that include complete resection are associated with prolonged disease-free survival and/or overall survival [10–12, 18–27]. Hence, the ATA thyroid guidelines recommend that as unresected ATC is almost certainly lethal, surgery should be performed when technically possible and if not likely to cause unacceptable morbidity [13]. According to TNM staging [28], all ATCs are stage IV. Stage IVA lesions are intrathyroidal, stage IVB involves gross extrathyroidal extension, and stage IVC disease includes distant metastasis. Stage IVA tumours are resectable; however, stage IVB tumours may be considered either resectable or unresectable. This decision will depend largely on local technical expertise of the surgeon and so in reality this distinction can be very variable. The ATA guidelines for ATC recommend that the aim of surgery is for gross clearance rather than tumour debulking. Using Edge et al.'s residual tumour classification as shown in Table 2 [28], ATA guidelines recommend surgery when a result of R0/R1 can be achieved; however, incomplete resection or tumour debulking (R2) is not recommended. This is contradictory to Haigh et al.'s [12] findings who noted aggressive surgery to be worthwhile in selective cases when combined with chemotherapy and/or radiotherapy even if some macroscopic disease has to be left behind to preserve organ function. This would reflect our own findings, as all surgically treated patients were noted to have residual macroscopic disease in our series (R2); yet a prolonged overall survival was observed compared to nonsurgically treated patients. Indeed, our one long-term survivor (>8 years+ at time of follow-up) also had tumour debulking rather than macroscopic clearance prior to radiotherapy:

Treatment regimens that include surgical resection are associated with prolonged disease-free survival and/or overall survival. The aim of surgery is for gross clearance rather than tumour debulking. Occasionally it may be necessary to leave residual macroscopic disease in order to preserve organ function.

4.3. Radiotherapy. The ATA guidelines recommend that definitive radiotherapy should be offered after complete or near complete surgical resection (R0/R1) in patients with a good performance status with no metastatic disease. This recommendation largely comes from the Surveillance, Epidemiology, and End Results (SEER) database of 516 patients from which Kebebew et al. found that this combination of treatment was associated with lower cause-specific mortality on multivariate analysis [8]. Studies also suggest that high dose radiotherapy can also be of benefit for patients who have only had an R2 resection, have unresectable disease, or have limited metastatic disease [29] in order to improve survival by controlling local symptoms, plus by potentially reducing tumour size, hence allowing subsequent surgery.

The dose of radiotherapy appears to be of importance with several studies demonstrating a clear improvement in survival of patients given higher doses of radiotherapy. For example, Wang et al. [30] reported a median overall survival of 11.1 months in patients treated with radical radiotherapy (>40 Gy) compared to only 3.2 months in patients treated with a palliative dose (<40 Gy) (P < 0.001), a result reflected in several other studies [10, 11, 23, 30]. High dose radiation was considered to be 40 Gy or greater in most studies. Performance status may play a part in these results, but the

| Residual tumour classification | Description |
|--------------------------------|-------------|
| R0                             | No residual tumour |
| R1                             | Macroscopic residual tumour |
| R2                             | Presence of residual tumour cannot be assessed |

- Table 2: Residual tumour classification from edge et al.; AJCC cancer staging manual [28].
message still remains that high dose radiotherapy is optimal if performance status allows.

Intensity-modulated radiation therapy (IMRT) is an advanced mode of high-precision radiotherapy that allows the radiation dose to conform more precisely to the 3D shape of the tumour, hence allowing higher radiation doses to be focused on complex tumour shapes whilst sparing surrounding normal structures. This allows higher and more effective radiation doses to be delivered to tumours with fewer side effects. Although IMRT has been suggested to improve outcome with reduced side effects in other head and neck and differentiated thyroid cancers [31–34], there is currently a lack of clear evidence for this with ATC. However, due to the favourable results for non-ATC patients, when available, IMRT may be a preferred option for ATC patients compared to conventional radiotherapy [35].

Definitive radiotherapy should be offered ideally after complete or near complete surgical resection (R0/R1) in patients with a good performance status with no metastatic disease. Higher doses (>40 Gy) and IMRT are preferable to improve outcome and reduce toxicity.

4.4. Asphyxiation. Radiotherapy given solely to prevent death from asphyxiation may not be worthwhile. Certainly, in our series in which the median dose given was 30 Gy, radiotherapy to prevent death from asphyxiation was futile. Surgery plus higher dose radiotherapy may be required. Additionally, strategies using hyperfractionated concurrent chemoradiotherapy seem to be more effective in local control than conventional fractionation or radiotherapy alone [36, 37]. Randomised studies incorporating QOL assessment are needed to confirm these findings. The ATA thyroid guidelines recognise the controversy regarding tracheostomy placement for airway preservation [8, 13, 19, 38–40], stating that tracheostomy or stent placement is best avoided unless there is impending airway compromise. However, this is noted to only be of temporary benefit as these patients are likely to have an extremely poor prognosis. Attempt at asphyxiation prevention via surgical excision is not recommended unless as part of tracheostomy insertion (thyromuscosomy or debulking of pretracheal tumour for access) rather than as a definitive procedure on its own [13]:

Low dose radiotherapy alone to prevent death from asphyxiation may be futile. Tracheostomy or stent placement is best avoided unless there is impending airway compromise, and is likely to be of only temporary benefit. Surgical excision is only recommended if part of a tracheostomy insertion.

4.5. Chemotherapy. If patient performance status allows, most studies suggest that multimodality treatment regimens which include chemotherapy are of benefit to produce the longest median survival [10, 12, 18, 21, 41–43]. There is currently no general consensus as to what chemotherapy regimens are best though several studies have compared different agents [5, 10, 12, 21, 36, 44–46]. The ATA guidelines summarise the trials by recommending some combination of a taxane (paclitaxel or docetaxel) and/or anthracyclines (doxorubicin) and/or platin (cisplatin or carboplatin). These are recommended as part of multimodal therapy [13]. If facilities allow for the quick setup and initiation of concurrent treatment either post-op or in the inoperable setting, concurrent chemoradiotherapy is thought to produce the greatest survival advantage [10, 12, 45–47]. However, side effects and the possible deterioration in quality of life whilst undergoing toxic regimens must be considered when embarking on multimodal therapy. Hence, importance should be placed on the patients active involvement in the decision making process. Future research which includes less toxic chemotherapeutic regimens incorporating QOL assessment in clinical trial settings is urgently needed:

Multimodality regimens which include chemother-apy improve median survival outcomes. Due to QOL issues whilst undertaking toxic regi-ments, importance is placed on the involvement of patients in the decision making process, balancing survival benefit versus possible side effects.

4.6. Biological Agents/Trials. Although the literature suggests that multimodal therapy improves survival of ATC patients, outcomes are still poor. There is even less evidence to substantiate whether these toxic regimens are actually of benefit in terms of quality of life and survival of patients specifically with advanced metastatic disease [13]. Hence, research into novel agents that improve outcomes whilst limiting toxicity is ongoing and vital. A range of molecular targeting agents that have been tested in small clinical trials of ATC (summarised in Table 3) might represent viable therapeutic options with a promising disease control rate ranging from 33% to 75% [48]. Another recent phase II/III study (FACT trial) using carboplatin, paclitaxel, and fosbretabulin (CA4P) versus carboplatin and paclitaxel looks promising as it reported a 1-year survival of 33.3% versus 77%, respectively [49]. The trial was closed early due to low accrual rate. A larger sample size trial is needed to confirm statistically significant difference in survival. As per ATA guidelines, patients with advanced or metastatic ATC wishing an aggressive approach should be encouraged to enter clinical trials investigating novel biological agents:

Research into novel agents that improve outcomes whilst limiting toxicity are ongoing and vital. Patients with advanced or metastatic ATC wishing an aggressive approach, should be encouraged to enter clinical trials investigating novel biological and molecular targeting agents.

5. Conclusion

Results from our case series of 20 patients with ATC are poor with median survival at 59 days and one-year survival at only 5%. The addition of chemotherapy to our treatment regime led to an observed improvement in survival. In order to
improve outcomes of ATC, a multimodality approach incorporating surgery, radiotherapy, and chemotherapy needs to be adopted when patient performance status allows. Chemotherapy appears to increase survival; however, toxic regimens can be poorly tolerated. Research into novel molecular targeting agents is urgently required.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgment**

The authors thank Mr. Ric Swindell, Department of Medical Statistics, for his help in statistical analysis.

**References**

[1] F. D. Gilliland, W. C. Hunt, D. M. Morris, and C. R. Key, “Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) Program 1973–1991,” *Cancer*, vol. 79, no. 3, pp. 564–573, 1997.

[2] S. H. Landis, T. Murray, S. Bolden, and P. A. Wingo, “Cancer statistics,” *Cancer Journal for Clinicians*, vol. 48, no. 1, pp. 6–29, 1998.

[3] C. Are and A. R. Shaha, “Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches,” *Annals of Surgical Oncology*, vol. 13, no. 4, pp. 453–464, 2006.

[4] Y. Kitamura, K. Shimizu, M. Nagahama et al., “Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases,” *Journal of Clinical Endocrinology and Metabolism*, vol. 84, no. 11, pp. 4043–4049, 1999.

[5] A. Bhatia, A. Rao, K.-K. Ang et al., “Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy,” *Head and Neck*, vol. 32, no. 7, pp. 829–836, 2010.

[6] S. C. Remick, G. Nagaiah, A. Hossain, C. J. Mooney, and J. Parmentier, “Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment,” *Journal of Oncology*, vol. 2011, Article ID 542358, 13 pages, 2011.

[7] B. McIver, I. D. Hay, D. F. Giuffrida et al., “Anaplastic thyroid carcinoma: a 50-year experience at a single institution,” *Surgery*, vol. 130, no. 6, pp. 1028–1034, 2001.

[8] E. Kebebew, F. S. Greenspan, O. H. Clark, K. A. Woebner, and A. McMillan, “Anaplastic thyroid carcinoma: treatment outcome and prognostic factors,” *Cancer*, vol. 103, no. 7, pp. 1330–1335, 2005.

[9] T. Yau, C. Y. Lo, R. J. Epstein, A. K. Y. Lam, K. Y. Wan, and B. H. Lang, “Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy,” *Annals of Surgical Oncology*, vol. 15, no. 9, pp. 2500–2505, 2008.

[10] A. T. Swaak-Kragten, J. H. W. de Wilt, P. I. M. Schmitz, M. Bontenbal, and P. C. Levendag, “Multimodality treatment for anaplastic thyroid carcinoma: treatment outcome in 75 patients,” *Radiotherapy and Oncology*, vol. 92, no. 1, pp. 100–104, 2009.

[11] J. Akaishi, K. Sugino, W. Kitagawa et al., “Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma,” *Thyroid*, vol. 21, no. 11, pp. 1183–1189, 2011.

[12] P. I. Haigh, P. H. Ituarte, H. S. Wu et al., “Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival,” *Cancer*, vol. 91, no. 12, pp. 2335–2342, 2001.

[13] R. C. Smallridge, K. B. Ain, S. L. Asa et al., “American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer,” *Thyroid*, vol. 22, no. 11, pp. 1104–1139, 2012.

[14] S. A. Hundahl, I. D. Fleming, A. M. Fremgen, and H. R. Menck, “A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995,” *Cancer*, vol. 83, no. 12, pp. 2638–2648, 1998.

[15] B. Roche, G. Larroumets, C. Dejaz et al., “Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the

**Table 3: Trials using molecular targeting agents in ATC.**

| Study | Year | Phase | Setting | Number of patients | Agent | Mechanism of action | Overall survival |
|-------|------|-------|---------|-------------------|-------|---------------------|-----------------|
| NCT01240590 (ClinicalTrials.gov) ongoing | 2010 | I/II | Recurrent, metastatic, and inoperable | 46 (planned) | Crolibulin plus cisplatin versus cisplatin alone | Microtubulin inhibitor | Awaiting |
| Savvides et al. [50] | 2013 | II | Advanced pretreated ATC | 20 | Sorafenib alone | Multikinase inhibitor with activity against Raf, VEGF, PDGFR, Ret, and c-kit | 20% (1 year survival) |
| Sosa et al. [49] | 2012 | II/III | Advanced pretreated ATC | 80 | Fosbretabulin (CA4P) or placebo in combination with carboplatin/paclitaxel | VDA/tubulin-binding compound | 33% (1 year compared to 7% in control arm) |
| Ha et al. [51] | 2010 | II | Advanced pretreated ATC | 11 | Imatinib alone | TKI acting upon Bcr-ABL and PDGF | 45% (6 months) |

ATC: anaplastic thyroid carcinoma; VEGF: vascular endothelial growth factor; PDGFR: platelet derived growth factor receptor; CA4P: Combretastatin A-4 phosphate; VDA: vascular disrupting agent; TKI: tyrosine kinase inhibitor.
literature," Annales d’Endocrinologie, vol. 71, no. 1, pp. 38–45, 2010.

[16] R. DeLellis, R. L. R, P. Heitz, and C. Eng, "World Health Organisa-
tion classification of tumours," in Pathology and Genetics of Tumours of Endocrine Organs, L. R. DeLellis R, P. Heitz, and C. Eng, Eds., IARC Press, Lyon, France, 1 edition, 2004.

[17] T. Kobayashi, H. Asakawa, K. Umesita et al., “Treatment of 37 patients with anaplastic carcinoma of the thyroid,” Head and Neck, vol. 18, no. 1, pp. 38–41, 1996.

[18] R. De Crevoisier, E. Baudin, A. Bachelot et al., “Combined treat-
ment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 60, no. 4, pp. 1137–1143, 2004.

[19] B. McIver, I. D. Hay, D. F. Giuffrida et al., “Anaplastic thyroid carcinoma: a 50-year experience at a single institution,” Surgery, vol. 130, no. 6, pp. 1028–1034, 2001.

[20] C. Passler, C. Scheuba, G. Prager et al., “Anaplastic (undiffer-
entiated) thyroid carcinoma (ATC): a retrospective analysis,” Langenbeck’s Archives of Surgery, vol. 384, no. 3, pp. 284–293, 1999.

[21] R. K. Tan, R. K. Finley III, D. Driscoll, V. Bakamjian, W. L. Hicks Jr., and D. P. Shedd, “Anaplastic carcinoma of the thyroid: a 24-
year experience,” Head and Neck, vol. 17, no. 1, pp. 41–48, 1995.

[22] E. J. Junor, J. Paul, and N. S. Reed, “Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy,” European Journal of Surgical Oncology, vol. 18, no. 2, pp. 83–88, 1992.

[23] J.-P. E. N. Pierie, A. Muzikansky, R. D. Gaz, W. C. Faquin, and M. J. Ott, “The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma,” Annals of Surgical Oncology, vol. 9, no. 1, pp. 57–64, 2002.

[24] V. Goutsouliak and J. H. Hay, “Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based study,” Clinical Oncology, vol. 17, no. 2, pp. 75–78, 2005.

[25] E. Brignardello, M. Gallo, I. Baldi et al., “Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years,” European Journal of Endocrinology, vol. 156, no. 4, pp. 425–430, 2007.

[26] M. Kihara, A. Miyauchi, A. Yamauchi, and H. Yokomise, “Prognostic factors of anaplastic thyroid carcinoma,” Surgery Today, vol. 34, no. 5, pp. 394–398, 2004.

[27] M. Schlumberger, C. Parmentier, M.-J. Delisle, J.-E. Couette, J.-P. Droz, and D. Sarrazin, “Combination therapy for anaplastic giant cell thyroid carcinoma,” Cancer, vol. 67, no. 3, pp. 564–566, 1991.

[28] S. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene, and A. Trotti, Eds., American Joint Committee on Cancer: Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010.

[29] P. C. Levendag, P. M. Z. R. de Porre, and W. L. J. Van Putten, “Anaplastic carcinoma of the thyroid gland treated by radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 26, no. 1, pp. 125–128, 1993.

[30] Y. Wang, R. Tsang, S. Ase, B. Dickson, T. Arenovich, and J. Brierley, “Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens,” Cancer, vol. 107, no. 8, pp. 1786–1792, 2006.

[31] C. M. Nutting, J. P. Morden, K. J. Harrington et al., “Parotid-
sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial,” The Lancet Oncology, vol. 12, no. 2, pp. 127–136, 2011.

[32] N. Lee, P. Xia, J. M. Quivey et al., “Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience,” International Journal of Radiation Oncology Biology Physics, vol. 53, no. 1, pp. 12–22, 2002.

[33] S. A. Bhide, R. Kazi, K. Newbould, K. J. Harrington, and C. M. Nutting, “The role of intensity-modulated radiotherapy in head and neck cancer,” Indian Journal of Cancer, vol. 47, no. 3, pp. 267–273, 2010.

[34] D. L. Schwartz, M. J. Lobo, K. K. Ang et al., “Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 4, pp. 1083–1091, 2009.

[35] J. Brierley, J. R. R, P. Warde, and Members of the IMRT Indications Expert Panel, “The role of IMRT in thyroid cancers,” in Program in Evidence-Based Care, Evidence-Based Series No.: 21-3-8, p. Cancer Care Ontario, Toronto, Canada, 2010.

[36] J. Tennvall, G. Lundell, P. Wahlberg et al., “Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery,” British Journal of Cancer, vol. 86, no. 12, pp. 1848–1853, 2002.

[37] D. E. Heron, S. Karimpour, and P. W. Grigsby, “Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups,” American Journal of Clinical Oncology, vol. 25, no. 5, pp. 442–446, 2002.

[38] H. T. Holting, H. Meybier, and H. Buhr, “Problems of tra-
cheostomy in locally invasive anaplastic thyroid cancer,” Langenbeck’s Archives für Chirurgie, vol. 374, no. 2, pp. 72–76, 1989.

[39] J. L. Pasieka, “Anaplastic thyroid cancer,” Current Opinion in Oncology, vol. 15, no. 1, pp. 78–83, 2003.

[40] A. R. Shaha, “Airway management in anaplastic thyroid carcino-
ma,” Laryngoscope, vol. 118, no. 7, pp. 1195–1198, 2008.

[41] M. J. Veness, G. S. Porter, and G. J. Morgan, “Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach,” ANZ Journal of Surgery, vol. 74, no. 7, pp. 559–562, 2004.

[42] B. Busnardo, O. Daniele, M. R. Pelizzo et al., “A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients,” Journal of Endocrinological Investigation, vol. 23, no. 11, pp. 755–761, 2000.

[43] O. Derbel, S. Limem, C. Ségura-Ferlay et al., “Results of combined treatment of anaplastic thyroid carcinoma (ATC),” BMC Cancer, vol. II, article 469, 2011.

[44] K. B. Ain, M. J. Egorin, and P. A. DeSimone, “Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion,” Thyroid, vol. 10, no. 7, pp. 587–594, 2000.

[45] M. Troch, O. Koperek, C. Scheuba et al., “High efficacy of concomitant treatment of undifferentiated (anaplastic) thy-
roid cancer with radiation and docetaxel,” Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 9, pp. E54–E57, 2010.

[46] R. L. Foote, J. R. Molina, J. L. Kasperbauer et al., “Enhanced sur-
vival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy,” Thyroid, vol. 21, no. 1, pp. 25–30, 2011.

[47] N. Onoda, S. Kashiwagi, S. Noda et al., “High efficacy of chemoradiation therapy sensitized by weekly docetaxel for
anaplastic thyroid cancer," *Anticancer Research*, vol. 33, no. 8, pp. 3445–34458, 2013.

[48] F. Perri, G. D. Lorenzo, G. D. Scarpati, and C. Buonerba, "Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options," *World Journal of Clinical Oncology*, vol. 2, no. 3, pp. 150–157, 2011.

[49] J. A. Sosa, J. Balkissoon, S. -P. Lu et al., "Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer," *Surgery*, vol. 152, no. 6, pp. 1078–1087, 2012.

[50] P. Savvides, G. Nagaiah, P. Lavertu et al., "Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid," *Thyroid*, vol. 23, no. 5, pp. 600–604, 2013.

[51] H. T. Ha, J. S. Lee, S. Urba et al., "A phase II study of imatinib in patients with advanced anaplastic thyroid cancer," *Thyroid*, vol. 20, no. 9, pp. 975–980, 2010.